Alligator Bioscience AB enters into drug development collaboration with major European pharmaceutical company

18-Oct-2005

Alligator Bioscience announces the signing of a collaboration agreement with a major European drug company for the optimization of a protein, using Alligator's proprietary ssDNA recombination technology, FINDTM.

According to the agreement Alligator Bioscience will receive milestone payments for the development as well as milestone payments during the clinical development of the final product.

Commenting on the agreement, Gun-Britt Fransson, CEO of Alligator Bioscience, says "We are very pleased to have entered this agreement and started to build a trustful relation with our partner. This enables us to furthermore build and explore the efficiency and uniqueness of the FINDTM technology while providing our customer with improved versions of the therapeutic protein".

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances